|
||
Luminal Kern pharma Pregnancy |
||
According to some reports the use of Luminal Kern pharma as an anticonvulsant during pregnancy leads to disruption of blood clotting in a newborn and can cause bleeding in the early postpartum period (usually within the first 24 hours after birth).
If barbiturates are used during childbirth there are encouraged to take delivery in intensive care availability.
Barbiturates are excreted in breast milk. Receiving barbiturates by nursing mother may cause CNS depression in the infant.
Rhea Luminal Kern pharma as an inducer of microsomal oxidation enzymes in the liver and increases its detoxifying function, reduces the concentration of bilirubin in serum. This property makes it appropriate use of Luminal Kern pharma in hemolytic disease of the newborn.
Not recommended. Excreted into human milk: Yes Comments: -Breastfed infants should be monitored for sedation, weight gain, and developmental milestones, especially in younger infants who are exclusively breastfed or during concomitant use with psychotropic drug combinations. -If toxicity is a concern, infant serum concentration of this drug should be obtained.
Excretion of this drug into breastmilk is highly variable. Breastfed infants showed increased sedation and suckling difficulties compared to infants that were not exposed to this drug. Reports of infantile spasms and withdrawal symptoms in infants occurred after abrupt discontinuation. Since this drug is excreted in breastmilk, methemoglobinemia is another potential risk.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|